Company Research Report: Remedee Labs

Company Overview

Name:

Remedee Labs

Mission of the Company:

Changing the lives of people with chronic pain by combining an endorphin stimulator based on millimeter waves with a personalized support program.

Founded:

• Year: 2016

• Founders: Jacques Husser, Dr. David Crouzier, and Michael Foerster

Key People:

• Jacques Husser: Co-founder and President Executive

• David Crouzier (PhD): Co-founder and CEO

• Michael Foerster: Co-founder and Chief Technology Officer

• Gilles Litman: Chief Business Officer

Headquarters:

99 Chemin de l’étoile, 38330 Montbonnot-Saint-Martin, France

Number of Employees:

• 40 employees

Revenue:

• No information is available

Known For:

• The company is known for developing the first endorphin stimulator bracelet using millimeter wave technology for the treatment of chronic pain, specifically fibromyalgia and osteoarthritis.

Products

Product Offerings:

1. Bracelet Remedee™

• High-Level Description:

• A millimeter wave-based bracelet that stimulates endorphins to relieve pain.

• Key Features:

• Uses 60 GHz millimeter waves for neuromodulation.

• Stimulates endorphin release to regulate pain perception, and improves overall quality of life including sleep, fatigue, and stress.

• Accompanied by a personalized support and digital tracking program.

Key Benefits:

• Provides a non-pharmacological treatment for managing chronic pain.

• Clinically validated for conditions such as fibromyalgia and osteoarthritis.

Recent Developments

Recent Advancements:

• New Certifications:

• Became the first clinically validated and certified medical device in Europe for fibromyalgia treatment (2024).

• Facility and Collaboration:

• Opened capital with Tudigo platform for further development (April 2024).

• Partnership with UPSA for a comprehensive approach to chronic pain management (2023).

• Clinical Outcomes:

• Positive clinical trials for treating osteoarthritis and fibromyalgia with significant improvements in pain relief, fatigue, anxiety, depression, and sleep quality (2023).

• Regulatory Progress:

• Achieved the status of "innovative device" by the FDA in the USA for fibromyalgia management (2022).

New Product/Feature Launches:

• No new products launched outside of existing offerings.

• Ongoing enhancements in support programs: remote coaching and personalized tracking to enhance user experience and effectiveness.

Partnerships:

• Strategic partnership with Generali France as both investor and partner (2022).

• Collaboration with CEA-Leti and ST Microelectronics for technology development.

Market Position and Strategy

• Positioned as a leader in healthtech with pioneering technology for chronic pain management.

• Focus on non-pharmacological treatments reflects a growing market trend towards integrated healthcare solutions.

• Aggressive push into European markets to expand accessibility of their innovative medical device.

Future Goals:

• Obtain reimbursement agreements to increase accessibility of treatment options.

• Continue to validate and enhance the therapeutic indications of their technology for broader chronic pain conditions.

Conclusion:

Remedee Labs stands as a vanguard in pain management by harnessing advanced technologies to create groundbreaking, non-pharmacological treatment options for chronic conditions like fibromyalgia.